Wegovy for $299? Retail Buzz Erupts As WeightWatchers, Novo Nordisk Expand Obesity Drug Push

Retail chatter around WW International surged Tuesday after the company’s expanded collaboration with Novo Nordisk officially began on July 1, offering broader access to the FDA-approved weight loss drug Wegovy through the WeightWatchers Clinic.

Under the partnership, prescriptions are fulfilled via NovoCare Pharmacy, with CenterWell Pharmacy handling distribution and home delivery. 

Members of the WeightWatchers Clinic also gain access to bundled pricing, shipment tracking, and inventory visibility.

The spike in trader activity followed the announcement of a new limited-time cash price offer by Novo Nordisk. 

Eligible self-pay patients can access Wegovy for $299 through July 31, up from a prior offer of $199 that expired on June 30. 

Those who redeemed the earlier $199 offer remain eligible for one fill at $299 in July, after which the monthly price rises to $499.

The development builds on Novo Nordisk’s statement last week that the collaboration with WeightWatchers aims to simplify the patient experience by integrating medication access with lifestyle support. 

Both companies also plan to explore future real-world research to evaluate outcomes from pairing Wegovy with WeightWatchers’ behavioral programs.

The expanded collaboration comes amid Novo Nordisk’s broader strategy to dominate the obesity treatment space. 

The company recently said it is advancing both oral and injectable formulations of its investigational drug amycretin, a dual GLP-1 and amylin receptor agonist.

Early trials showed up to 24.3% weight loss with the highest injectable dose and 13.1% with a high-dose oral version. 

Neither trial showed a plateau in weight reduction.

Separately, data from the Phase 3b STEP UP trial showed that a higher 7.2 mg dose of Wegovy led to an average weight loss of 21% over 72 weeks, with one-third of participants losing 25% or more. 

Novo said it will pursue regulatory approval for the new dose.

On Stocktwits, WW International saw ‘bullish’ retail sentiment alongside ‘extremely high’ message volume, while sentiment for Novo Nordisk was ‘bearish’ with ‘low’ message activity.

WW International’s stock has dropped 78.5% year-to-date, while Novo Nordisk shares are down 20.2% over the same period.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on